Measuring extent of surface contamination produced by the handling of antineoplastic drugs in low- to middle-income country oncology health care settings

References

• Centers for Disease Control and Prevention. NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Cincinatti, OH: Department of Health and Human Services, National Institute for Occupational Safety and Health, Pub No. 2004-165; September 2004.
   Google Scholar
• Menonna-Quinn D. Safe handling of chemotherapeutic agents in the treatment of nonmalignant diseases. J Infus Nurs 2013;36:198–204.
   PubMedGoogle Scholar
• Del Gaudio D, Menonna-Quinn D. Chemotherapy: occupational Hazards. Am. J. Nurs. 1998;98:59–65.
   PubMed Web of Science ®Google Scholar
• Connor T, McDiarmid M. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin. 2006;56:354–365.
   PubMed Web of Science ®Google Scholar
• Hedmer M, Tinnerberg H, Axmon A. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health. 2008;81:899–911.
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. http://monographs.iarc.fr/ENG/Classification/. Accessed June 2016.
   Google Scholar
• The National Institute for Occupational Safety and Health. Occupational exposures to antineoplastic agents and other hazardous drugs. https://www.cdc.gov/niosh/topics/cancer/. Accessed June 2016.
   Google Scholar
• McDiarmid M, Oliver M, Roth T, et al. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Medicine. 2010;52:1028–1034.
   PubMed Web of Science ®Google Scholar
• Hedmer M, Wholfart G. Hygienic guidance values for wipe sampling of antineoplastic drugs in Swedish hospitals. J Environ Monit. 2012;14:1968–1975.
   PubMed Web of Science ®Google Scholar
• Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health-Syst Pharm 1996;53:2713–2723.
   PubMed Web of Science ®Google Scholar
• Zeedijk M, Greijdanus B, Steenstra FB, Uges DRA. Monitoring exposure to cytotoxics on the hospital ward: measuring surface contamination of four different cytotoxic drugs from one wipe sample. Eur J Hosp Pharm Sci. 2005;11:18–22.
   Google Scholar
• Polovich M, Bolton DL, Eisenberg S, et al. Safe Handling of Hazardous Drugs. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2011.
   Google Scholar
• OSHA. Guidelines for Cytotoxic (Antineoplastic) Drugs. Washington, DC: United States Department of Labor, Occupational Safety and Health Administration, Publication No 8-1.1; January 1986.
   Google Scholar
• OSHA Directorate of Technical Support. Controlling Occupational Exposure to Hazardous Drugs. United States Department of Labor, Occupational Safety and Health Administration, Instruction TED 1.15; September 1995.
   Google Scholar
• OSHA Directorate of Technical Support. Controlling Occupational Exposure to Hazardous Drugs. United States Department of Labor, Occupational Safety and Health Administration, Instruction TED 1.15; January 1999.
   Google Scholar
• American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic drugs in hospitals. Am J Hosp Pharm. 1985;42:131–137.
   Google Scholar
• Oncology Nursing Society Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh: Oncology Nursing Press; 1996.
   Google Scholar
• International Society of Oncology Pharmacy Practitioners. Standards of practice: safe handling of cytotoxics. J Oncol Pharm Pract. 2007;13:1–81.
   PubMedGoogle Scholar
• United States Pharmacopeial Convention. Pharmaceutical compounding-sterile preparations. In: The United States Pharmacopeia and The National Formulary. 36th ed. Rockville, MD: United States Pharmacopeial Convention; 2012:361–398.
   Google Scholar
• Sessink P. Environmental contamination with cytostatic drugs: past, present and future. Safety Considerations in Oncology Pharmacy. 2011( Special Edition, Fall):1–3.
   Google Scholar
• Schierl R, Böhlandt A, Nowak D. Guidance values for surface monitoring of antineoplastic drugs in German pharmacies. Ann Occup Hyg. 2009;53:703–711.
   PubMed Web of Science ®Google Scholar
• Nussbaumer S, Geiser L, Sadeghipour F, et al. Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces. Anal Bioanal Chem. 2012;402:2499–2509.
   PubMed Web of Science ®Google Scholar
• Connor T, DeBord G, Pretty J, et al. Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J of Occup & Environ Medicine. 2010;52:1019–1027.
   PubMed Web of Science ®Google Scholar
• Jeronimo M, Colombo M, Astrakianakis G, et al. A surface wipe sampling and LC-MS/MS method for the simultaneous detection of six antineoplastic drugs commonly handled by healthcare workers. Anal Bioanal Chem. 2015;407:7883–7092.
   Web of Science ®Google Scholar
• Guillemette A, Langlois H, Voisine M, et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of the IV tubing in the pharmacy and use of a closed-system transfer device. J Oncol Pharm Practice. 2014;20:426–432.
   PubMed Web of Science ®Google Scholar
• Fleury-Souverain S, Nussbaumer S, Mattiuzzo M, et al. Determination of the external contamination and cross-contamination by cytotoxic drugs on the surfaces of vials available on the Swiss market. J Oncol Pharm Practice. 2014;20:100–111.
   PubMed Web of Science ®Google Scholar
• Wakui N, Ookubo T, Iwasaki Y, et al. Development of a closed drug preparation method for oral anticancer drugs. J Oncol Pharm Practice. 2013;19:315–320.
   PubMedGoogle Scholar
• Bussieres J, Tanguay C, Touzin K, et al. Environmental contamination with hazardous drugs in Quebec hospitals. Can J Hosp Pharm. 2012;65:428–435.
   PubMedGoogle Scholar
• The World Bank. Data: World Bank country and lending groups. http://data.worldbank.org/about/country-and-lending-groups#Upper_middle_income. Accessed June 2016.
   Google Scholar
• Turci R, Sottani C, Spagnoli G, et al. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B. 2003;789:169–209.
   PubMed Web of Science ®Google Scholar
• Pretty J, Connor T, Spasojevic I, et al. Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment. J Oncol Pharm Practice. 2010;18:23–36.
   PubMedGoogle Scholar
• Larson R, Khazaeli B, Dillon K. Development of an HPLC method for simultaneous analysis of five antineoplastic agents. App Occup Env Hyg. 2003;18:109–119.
   PubMedGoogle Scholar
• Berruyer M, Tanguay C, Caron N, et al. Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study. J Occup Env Hyg. 2015;12:87–94.
   PubMed Web of Science ®Google Scholar
• Hon CY, Teschke K, Chu W, et al. Antineoplastic drug contamination of surfaces through the hospital medication system in Canadian hospitals. J Occup Environ Hyg. 2013;10:374–383.
   PubMed Web of Science ®Google Scholar
• Larson R, Khazaeli B, Dillon K. Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health-Syst Pharm. 2002;59:270–277.
   PubMed Web of Science ®Google Scholar
• Müller-Ramírez C, Squibb K, McDiarmid M. Accessible analytical methodology for assessing work place contamination of antineoplastic drugs in limited-resource oncology health care settings. J Anal Sci Tech. 2016 ahead of print. doi:10.1186/s40543-016-0091-8.
   Google Scholar
• Sessink P, Leclercq G, Wouters DM. Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation. J Oncol Pharm Practice. 2015;21:118–127.
   PubMed Web of Science ®Google Scholar
• Sessink P, Traban J, Coyne J. Reduction in surface contamination with cyclophosphamide in 30 US hospitals pharmacies following implementation of a closed-system drug transfer device. Hosp Pharm. 2013;48:204–212.
   PubMedGoogle Scholar
• Miyake T, Iwamoto T, Tanimura M, et al. Impact of closed-system transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. SpringerPlus. 2013;2:273. doi:10.1186/2193-1801-2-273.
   PubMed Web of Science ®Google Scholar
• Ramphal R, Bains T, Vaillancourt R, et al. Occupational exposure to cyclophosphamide in nurses at a single center. J Occup Environ Med. 2014;56:304–312.
   PubMed Web of Science ®Google Scholar
• Kopp B, Schierl R, Nowak D. Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings. Int Arch Occup Environ Health. 2013;86:47–55.
   PubMed Web of Science ®Google Scholar
• Odraska P, Dolezalova L, Kuta J, et al. Association of surface contamination by antineoplastic drug with different working conditions in hospital pharmacies. Arch Env Occup Health. 2015;69:148–158.
   Web of Science ®Google Scholar
• Kiffmeyer T, Tuerk J, Hahn M, et al. Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies—the MEWIP project. Ann Occup Hyg. 2013;4:444–455.
   Web of Science ®Google Scholar
• Merger D, Tanguay C, Langlois E, et al. Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals. Int Arch Occup Environ Health. 2014;87:307–313.
   PubMed Web of Science ®Google Scholar
• Connor TH, Zock MD, Snow AH. Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: methodology and recommendations. J Occ Environ Hyg. 2016;13:658–667. doi:10.1080/15459624.2016.1165912.
   PubMed Web of Science ®Google Scholar